In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal opposed reactions occurred in three.3% of 429 patients. Serious…
You can always talk to gross sales if you’re interested in advanced plans. Please remember to enter all contact and…
This website uses cookies.